g
[ 1] A meta-analysis was performed of clinical trials involving acetazolamide
Reasons of acetazolamide (ACTZ) inefficacy in patients with severe
In patients with COPD, the condition is called post-hypercapnic alkalosis
1399-6576
Acetazolamide is a non-selective carbonic anhydrase inhibitor that inhibits renal tubular reabsorption of bicarbonate, leading to urinary alkalisation and metabolic acidosis
This generally includes an acute change in one or more of the following cardinal symptoms: Cough increases in frequency and severity
Case Report
Antibiotica zijn effectief bij de exacerbaties van COPD die gepaard gaan met een toename van de dyspneu en het opgeven van purulent sputum
If left untreated, it can progress to dyspnea at rest, rales, cyanosis, and a
) Acetazolamide can temporarily cause carbonated drinks to taste unpleasant
Reversal of metabolic alkalosis may facilitate weaning from mechanical ventilation of patients with COPD
due to over-diuresis)(10)
We tested this hypothesis in a randomized, placebo-controlled, double
This review examines the literature and indications for acetazolamide use in patients with COPD dating back to its initial release 6 decades ago
15, hypoxia) for 15 min
The same phenomenon has also been described in severe asthma, community-acquired pneumonia and obesity
20 mg The article talks about “can’t breath” and “won’t breath”, the idea is that using the acetazolamide will cause metabolic acidosis which will need to be corrected by hyperventilation and thus correct the “won’t breath” and decrease the pCO2